Bupivacaine - Cellix Bio

Drug Profile

Bupivacaine - Cellix Bio

Alternative Names: CLX 117

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellix Bio
  • Developer Cellix Bio; RVL
  • Class Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mucositis
  • Discontinued Postoperative pain

Most Recent Events

  • 24 Apr 2018 Discontinued - Preclinical for Postoperative pain in India (unspecified route) (Cellix Bio pipeline, April 2018)
  • 20 Feb 2018 Cellix Bio announces intention to file IND for oral Mucositis in 2018
  • 20 Feb 2018 Cellix Bio has patent protection and pending patent applications for compositions and methods for the treatment of oral Mucositis in USA, before February 2018 (Cellixbio pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top